Clinical trial · Interventional
EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer
Evaluation of Hypoxia by EF5 (NSC#684681) Binding in Cervix Cancer
NCT00049231CI-TRIAL-00011010completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 may be effective in measuring oxygen in tumor tissue and helping to predict the effectiveness of anticancer therapy. PURPOSE: Diagnostic trial to study the effectiveness of EF5 in detecting tumor hypoxia in patients who have stage IIB, stage IIIB, or stage IVA cervical cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy | Procedure | — | UNRESOLVED |
| EF5 | Drug | — | UNRESOLVED |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically confirmed invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix * Stage IIB, IIIB, or IVA * Primary disease * No prior treatment * Must be enrolled on GOG-0191 protocol PATIENT CHARACTERISTICS: Age * 18 and over Performance status * GOG 0-3 Life expectancy * Not specified Hematopoietic * See Disease Characteristics * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic * Bilirubin no greater than 1.5 times normal * SGOT no greater than 3 times normal * Alkaline phosphatase no greater than 3 times normal * Hemoglobin less than 13 g/dL Renal * Creatinine no greater than 2 mg/dL Cardiovascular * No cardiac disease that would preclude safe administration of necessary fluid volumes Pulmonary * No chronic pulmonary disease that would preclude safe administration of necessary fluid volumes Other * No history of grade 3 or 4 peripheral neuropathy * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Must weigh no more than 180 kg PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified
References
Publications (0)
Data not yet available
No reference posted for this study.